Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary Cutter, Gavin Giovannoni, Joep Killestein, Heinz Wiendl, Karen Smirnakis, Shan Xiao, George Kong, Robert Kuhelj, Nolan Campbell, Anneke van der Walt, Chris Dwyer, Katherine Buzzard, Judith Spies, John Parratt, Vincent Van Pesch, Barbara Willekens, Gaetano Perrotta, E Bartholomé, François Grand’Maison, François Jacques, Paul S Giacomini, Reza Vosoughi, Jean-Marc Girard, de Sèze, Christine Lebrun‐Frénay, Aurélie Ruet, David Laplaud, Gerd Reifschneider, Bert Wagner, Sebastian Rauer, Refik Pul, Maria Seipelt, Achim Berthele, Luisa Klotz, Boris-Alexander Kallmann, Friedemann Paul, Anat Achiron, Giacomo Lus, Diego Centonze, Francesco Patti, Luigi Maria Edoardo Grimaldi, Raymond Hupperts, S. T. F. M. Frequin, Jiske Fermont, Sara Eichau Madueño, Ana Alonso, Lucienne Costa-Frossard França, José Meca-Lallana, Luís Brieva, Owen Pearson, David Rog, Nikolaos Evangelou, Azza Ismail, Ellen Lathi, Edward Fox, Thomas Leist, Jacob A. Sloane, Gregory F. Wu, Bhupendra Khatri, Brian Steingo, Ben Thrower, Mark Gudesblatt, Jonathan Calkwood, Daniel S. Bandari, John Scagnelli, Christopher LaGanke, Derrick Robertson, Lucas Kipp, Martin Belkin, Stanley Cohan, Lawrence Goldstick, Ardith Courtney, Wendy Vargas, Andrew Sylvester, Jayshri Srinivasan, Meena Kannan, Maryann Picone, Jeffrey English, Salvatore Napoli, Roumen Balabanov, Islam Zaydan, Jacqueline Nicholas, Jeffrey Kaplan, Fred Lublin, Emily Riser, Tamara Miller, Enrique Álvarez, Sibyl Wray, Jeffrey B. Gross, Siddharama Pawate, Carrie M. Hersh, Lucas McCarthy, Heidi Crayton, Jennifer Graves